Researchers Detail Three Advances in Type 1 Diabetes Care
New developments in immunotherapy, stem cells, and smart insulin pumps signal a shift in treating type 1 diabetes.
Updated on Oct. 15, 2026 in Diabetes
Live Poll
Should local schools or healthcare systems implement mandatory screening for childhood diseases?
Medical experts at the Breakthrough T1D Clinical and Research Congress identified three core areas of progress to treat type 1 diabetes. These advancements include novel immunotherapies, stem cell research, and smart insulin pump technology.
Why it matters
Disease-modifying therapies and new technologies aim to halt the autoimmune destruction of beta cells. These developments represent a potential paradigm shift in the management and long-term care of the disease.
Researchers are building on the 1993 Diabetes Control and Complications Trial to advance three treatment areas, including Teplizumab-mzwv for stage 2 and 3 disease. The efficacy of combining beta cell transplants with disease-modifying therapies is still under study.
The players
Breakthrough T1D
This organization is a global leader in funding type 1 diabetes research and advocacy.
The details
Smart insulin pumps now utilize AI and sensors to automate delivery, while pluripotent stem cell technology allows for beta cell production. Additionally, Italy has passed a law requiring mandatory type 1 diabetes screening for children.
Timeline
1993: Diabetes Control and Complications Trial findings were published.
- 2026-10-15
Breakthrough T1D Clinical and Research Congress occurred.
The Big Picture
This research builds upon the 1993 Diabetes Control and Complications Trial by transitioning from reactive glycemic management to proactive disease modification. These developments signal a move away from legacy approaches that only mitigated symptoms.
Patients may soon have access to disease-modifying therapies like Teplizumab-mzwv to delay disease onset. Advanced insulin pump systems also promise more automated daily management for those already diagnosed.
The takeaway
The move toward disease-modifying therapy suggests a future where diabetes can be caught earlier or treated more effectively. Patients and families should discuss the current availability of immunotherapies for stage 2 or stage 3 disease with their healthcare providers.
Further reading
Learn more about evolving treatment options in the Diabetes section.
Live Poll
Should local schools or healthcare systems implement mandatory screening for childhood diseases?
